SciBase Gets Expanded FDA Approval
What happened
SciBase, a developer of AI-based skin disorder diagnostics, has received FDA approval for extended labeling in the U.S. The approval allows a wider range of healthcare professionals to use its AI diagnostic solutions, potentially broadening the technology's market access and adoption.
Why it matters
SciBase's core technology, Electrical Impedance Spectroscopy (EIS), distinguishes it from competitors focused on visual analysis. The Nevisense platform uses a probe with a disposable electrode to send small electrical signals into the skin, with the AI analyzing cellular structure based on impedance measurements, creating a recurring revenue model from
Quick answers
What happened in SciBase Gets Expanded FDA Approval?
SciBase, a developer of AI-based skin disorder diagnostics, has received FDA approval for extended labeling in the U.S. The approval allows a wider range of healthcare professionals to use its AI diagnostic solutions, potentially broadening the technology's market access and adoption.
Why does SciBase Gets Expanded FDA Approval matter?
SciBase's core technology, Electrical Impedance Spectroscopy (EIS), distinguishes it from competitors focused on visual analysis. The Nevisense platform uses a probe with a disposable electrode to send small electrical signals into the skin, with the AI analyzing cellular structure based on impedance measurements, creating a recurring revenue model from
